ποΈ Verified NIH Record β’ Updated 2025-07-01
Metabolic Response to Food in Lung Cancer (NCT05937074)
π΅ Active, Not Recruiting Interventional Protocol π Observational Clinical Research Sponsor: Pennington Biomedical Research Center
π©Ί Plain-English Summary (8th-Grade Level)
This goal of this study is to describe how unintentional weight loss influences fasting and post-prandial metabolic flexibility in participants with advanced non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: Pennington Biomedical Research Center β Baton Rouge, Louisiana
Age range: 18 Years
π§ͺ Interventions in This Study
- Weight loss (%) (OTHER)
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- Pennington Biomedical Research Center β Baton Rouge, Louisiana
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 β Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naΓ―ve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) β Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC β Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions β Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study β La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) β Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.